Omeros Target Lowered and 4 Stock Analyses to Track
Myriad Genetics Inc. (NASDAQ:MYGN): According to Leerink, risks from the Supreme Court’s gene patent case and reimbursement changes are being overly discounted in Myriad Genetics shares. The firm has decided to keep its Outperform rating and a $32-$34 price target rangem on the stock.
Barnes & Noble, Inc. (NYSE:BKS) is expected by Stifel Nicolaus to report a 2 percent rise in in-store sales during the holiday period compared to 2011, and this will be driven by strength in educational toys and games. The firm has predicted that NOOK revenue will see a boost of 12 percent year over year, but it keeps its Hold rating on the stock.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Target Corp. (NYSE:TGT) is predicted by Stifel Nicolaus to report holiday sales comps that did not reach Street expectations, due to slowing food sales and possibly weaker apparel sales. The firm keeps its Hold rating on the stock.
Cepheid (NASDAQ:CPHD): William Blair predicts that solid initial demand for Cepheid’s recently approved Xpert CT/NG from existing Xpert customers and projects 2013 sales between $15 million to $20 million globally. However, William Blair remains unsure if Cepheid can ship enough product to meet initial demand, considering the fact that it provided no update on the recent manufacturing issues. The firm reiterates its Outperform rating on the stock.
Omeros Corporation (NASDAQ:OMER) price target has been reduced by Burrill following the company’s announcement that OMS103HP was unable to meet its primary endpoint in patients that have been undergoing arthroscopic partial meniscectomy surgery. The firm has also mentioned that OMS103HP has reached statistically significant reduction of postoperative pain, and it reiterates its Outperform rating on the stock.